

**Review Article****Open Access****Pathologic changes in patients infected with SARS-CoV-2:
a review**

*¹Babazhitsu, M., ²Adegoke, O. O., ³Abayomi, S. A., and ⁴Adegboro, B.

¹Department of Medical Microbiology and Parasitology, Faculty of Basic Clinical Sciences, College of Health Sciences, Usmanu Danfodiyo University, Sokoto, Sokoto State, Nigeria

²Department of Pathology, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, Nigeria

³Department of Medical Microbiology and Parasitology, LAUTECH Teaching Hospital, Ogbomoso, Nigeria

⁴Department of Medical Microbiology and Immunology, Nile University of Nigeria, Abuja

*Correspondence to: babazhitsu.makun@udusok.edu.ng; +234 8032874925

Abstract:

Severe acute respiratory syndrome–coronavirus-2 (SARS-CoV-2) enters cells using the angiotensin converting enzyme 2 (ACE2), which are expressed by the respiratory tract endothelium, epithelial cells of the stomach, duodenum, ileum, rectum, cholangiocytes, and hepatocytes. Pathological examinations of these organs are not feasible method of diagnosis but can explain pathological changes, pathogenesis of the disease, and the cause of death in COVID-19 cases. In this review, we performed a literature search for COVID-19-related pathological changes seen during post-mortem examinations in different organs of the body including the lungs, gastrointestinal tract, liver, kidney, skin, heart and blood. Our findings showed that SARS-CoV-2 has damaging effects on many organs, probably due to the host immune responses to the presence of the virus. It is recommended that both antiviral and immunomodulatory agents should be considered in the management of COVID-19 patients for better prognosis, and clinical outcome.

Keywords: COVID-19, SARS-CoV-2, ACE-2, pathology, autopsy findings

Received Jun 21, 2021; Revised Aug 4, 2021; Accepted Aug 5, 2021

Copyright 2021 AJCEM Open Access. This article is licensed and distributed under the terms of the Creative Commons Attribution 4.0 International License [rel="license" href="http://creativecommons.org/licenses/by/4.0/">](http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided credit is given to the original author(s) and the source. Editor-in-Chief: Prof. S. S. Taiwo

**Changements pathologiques chez les patients infectés par le
SRAS-CoV-2: une revue**

*¹Babazhitsu, M., ²Adegoke, O. O., ³Abayomi, S. A., et ⁴Adegboro, B.

¹Département de microbiologie médicale et de parasitologie, Faculté des sciences cliniques de base, Collège des sciences de la santé, Université Usmanu Danfodiyo, Sokoto, État de Sokoto, Nigéria

²Département de pathologie, Faculté des sciences médicales de base, Collège de médecine, Université d'Ibadan, Nigéria

³Département de médecine Microbiologie et parasitologie, Hôpital universitaire LAUTECH, Ogbomoso, Nigéria

⁴Département de microbiologie médicale et d'immunologie, Université du Nil du Nigéria, Abuja

*Correspondance à: babazhitsu.makun@udusok.edu.ng ; +234 8032874925

Abstrait:

Le syndrome respiratoire aigu sévère-coronavirus-2 (SARS-CoV-2) pénètre dans les cellules à l'aide de l'enzyme de conversion de l'angiotensine 2 (ACE2), qui est exprimée par l'endothélium des voies respiratoires, les cellules épithéliales de l'estomac, du duodénum, de l'iléon, du rectum, des cholangiocytes, et les hépatocytes. Les examens pathologiques de ces organes ne sont pas une méthode de diagnostic réalisable, mais peuvent expliquer les changements pathologiques, la pathogenèse de la maladie et la cause du décès dans les cas de COVID-19. Dans cette revue, nous avons effectué une recherche bibliographique sur les changements pathologiques liés au COVID-19

observés lors d'examens post-mortem dans différents organes du corps, notamment les poumons, le tractus gastro-intestinal, le foie, les reins, la peau, le cœur et le sang. Nos résultats ont montré que le SRAS-CoV-2 a des effets néfastes sur de nombreux organes, probablement en raison des réponses immunitaires de l'hôte à la présence du virus. Il est recommandé que les agents antiviraux et immunomodulateurs soient pris en compte dans la prise en charge des patients COVID-19 pour un meilleur pronostic et des résultats cliniques.

Mots-clés: COVID-19, SARS-CoV-2, ACE-2, pathologie, résultats d'autopsie

Introduction:

In December 2019 an outbreak of a novel coronavirus disease was reported and subsequently declared a global pandemic (1). The World Health Organization (WHO) officially named the disease caused by the severe acute respiratory syndrome coronavirus - 2 (SARS-CoV-2) as coronavirus disease 2019 (COVID-19) (2). SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus belonging to the beta coronavirus family and is the seventh coronavirus that cause human infections (3). Among the other six coronaviruses that can cause diseases in humans are SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), which is associated with high mortality (4,5). SARS-CoV-2 is highly homologous to SARS-CoV and enters the cell via the angiotensin converting enzyme 2 (ACE-2).

COVID-19 notably present with symptoms of fever, dry cough, fatigue, muscle aches, shortness of breath, headache, diarrhea, and indigestion (6). It has been observed that from the onset of symptoms to death from the disease is between 6 and 41 days, and the average is 14 days (7). The aim of this review was to examine changes in various organs including the skin following infection by SARS-CoV-2. It is hoped that adequate knowledge of the pathology of the disease will aid early diagnosis and management of COVID-19, which can lead to reduction in mortality and length of hospital stay for the patients.

Methodology:

Online databases including the Web of Science, PubMed, Scopus, and Google Scholar were searched for relevant publications on the clinical features, pathogenesis, organ changes and complications in COVID-19 following the PRISMA guideline (8). We searched for pathological changes in terms of gross and microscopic morphology on autopsy, immuno-histochemistry, electron microscopy, fluorescence in-situ hybridization (FISH) and RT-PCR used to con-

firm SARS-COV-2 in these organs or tissues.

Search terms and phrases used include; "COVID-19 pathology", "COVID-19 autopsy findings", "COVID-19 diagnostic methods", "angiotensin-converting enzyme 2 (ACE2)", "SARS-CoV-2", "COVID-19", "2019-nCoV" and "organ changes in COVID-19". There was no restriction on the date, place, type of study, and inclusion/exclusion criteria but publications not written in English were excluded. With greatest sensitivity search, we found 382 articles on external databases collected using Endnote Software. All the articles from the cited databases were then unified to avoid duplicates. Following review of the titles and abstracts, non-relevant articles were excluded, leaving a total of 60 eligible articles for the review (Fig 1).

Results and Discussion:

COVID-19 and the lungs

The lungs are the most affected organ in COVID-19 (9). However, severity of its involvement ranges from lack of symptoms or mild pneumonia to severe hypoxia, shock, respiratory failure, and multiorgan failure or death is associated with critical form of the disease (10). Grossly the lungs are heavy, often 3-5 times the normal size with evidence of congestion and haemorrhagic necrosis (11). In over 80% of cases, microscopic examination revealed various stages of diffuse alveolar damage, including the exudative phase with hyaline membrane formation, the proliferative phase with type 2 pneumocyte hyperplasia, and the early repair phase with interstitial spindle cell hyperplasia and/or intra-alveolar organization (12).

Other methods have been used to detect SARS-CoV-2 in the lung tissues including electron microscopy, immunohistochemistry to detect viral antigens, immunofluorescence viral nucleic acid detection by in-situ hybridization (FISH), and reverse transcriptase polymerase chain reaction (RT-PCR) (13). Effort has been made to detect SARS-CoV-2 on electron microscopy which reported "virus-like particles" (14).




Fig. 1: Process of selection of publications (PRISMA guide) used for the review

In another study, it was reported that detection of SARS-CoV-2 by immuno-histochemistry was successful only in the lung, while no virus could be detected by this method in the heart, liver, kidney, small intestine, skin, adipose tissue, and bone marrow (15). Compared to immunohistochemistry, immunofluorescence has been used less frequently for the detection of SARS-CoV-2 proteins/antigens (16), and this could partly be due to stronger autofluorescence as a confounding factor and potential infectivity of frozen tissues.

COVID-19 and the heart

Clinical features in COVID-19 patients suggest that SARS-CoV-2 has a major impact on the heart. Patients have features which suggest acute myocardial injury, including consistently elevated serum troponin level and ECG changes (17). The pathophysiology and the degree of myocardial injury, along with the short and long-term cardiovascular outcomes in COVID-19 survivors remain unclear. However, autopsy studies of the heart in these patients suggest that pre-existing heart diseases were dominant, particularly hypertensive heart disease (18). In other post-mortem studies, the findings showed endothelitis, as well as myocardial infiltration with lymphocytes, while direct injury of cardiomyocytes by the virus was not confirmed (19-21)

One autopsy case series study revealed

severe right ventricular dilatation in patients, along with drop out myocyte necrosis and apoptosis. However there was no evidence of lymphocytic myocarditis suggesting that elevated troponin levels in these patients was due to extreme stress from acute pulmonary disease (22). Viruses with particular tropism for heart directly gain entrance to cardiomyocytes to cause their degeneration or to infect endothelial cells. These often lead to significant endothelial dysfunction, ischemia, cytokine release, and infiltration of myocardial tissue with immune cells (23). Consequently, innate and adaptive immune systems are activated, both being responsible for cytokine storm syndrome, as well as viral clearance.

Left ventricular systolic function impairment and cardiomyocytes dysfunction often lead to death (23). Of particular interest is the report of severe myocarditis and decreased systolic function after SARS-COV-2 infection, leaving us to wonder if the virus induces new cardiac pathologies or merely exacerbates underlying pathologies. It is obvious that as more studies are conducted and the disease evolves, more will be known about the long term effect of this virus on the heart (24).

COVID 19 and the kidney

Although, the first organs to be affected in SARS-COV-2 infection are the lungs, as initial clinical sign for the detection of COVID-19 is

pneumonia (25), many organ damages have been reported (6) and some cases of COVID-19 pneumonia present with kidney injury (26). Autopsy findings from patients who died of COVID-19 also revealed renal damage (27). Many studies have reported that SARS-CoV and SARS-CoV-2 use the ACE-2 to enter into target cells (28), and ACE-2 is well expressed on the surface of kidney tubular cells, which explains SARS-CoV-2 tropism for the kidney.

Many studies recognized the relevance of the inflammatory/immune-mediated reaction with the release of high levels of circulating harmful mediators such as IL-1, IL-6, TNF- α and chemokines capable of interacting with kidney-resident cells to cause endothelial dysfunction, microcirculatory derangement, and tubular injury (29). Acute kidney injury (AKI) developed on the average 9 days after admission together with secondary infections and acute cardiac damage (30). Many factors such as age, severity of illness, and the presence of diabetes mellitus contribute to AKI in patients with acute respiratory diseases (ARDS) (31).

The immune system responses to SARS-CoV-2 and direct cytotoxic effect of the virus may be responsible for AKI in COVID-19 (32). Studies have shown that severe COVID-19 patients have reduced levels of CD4⁺ (helper) and CD8⁺ (cytotoxic) T lymphocytes, NK cells, and high levels of inflammatory cytokines. As soon as SARS-CoV-2 infiltrates into the renal cells, innate immune system and inflammatory responses might be triggered causing a cytokine storm syndrome, which is responsible for hypoxia, shock, rhabdomyolysis and acute kidney injury (33,34).

COVID 19 and gastrointestinal system

Similar to abundant expression of ACE-2 in the lungs, it has also been demonstrated on the epithelial cells of the stomach, duodenum, ileum, rectum, cholangiocytes, hepatocytes of the liver and esophageal mucosa (35). From physiological point of view, the kidney and the gut share a strong association or synergy during the maintenance of internal milieu known as the gut-kidney axis, which is further divided into metabolism-dependent and immune pathways (34). Gastrointestinal symptoms such as vomiting, diarrhea, loss of appetite and abdominal pain have been reported in SARS-CoV and COVID-19 patients (36-38).

Post-mortem changes in the gastrointestinal linings include vasculitis and increased inflammatory infiltrates. The spleen demonstrates increased neutrophil numbers, while the

mesenteric lymph nodes show increased plasmablasts and congestion (39).

COVID-19 and the liver

Angiotensin converting enzyme-2 (ACE-2) is abundantly expressed in both the gastrointestinal epithelial cells and the liver, which explains a potential direct damage by SARS-CoV-2 on the liver (40). The liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, are elevated in COVID-19 patients, which indicate liver injury in these patients. AST elevation is more common than ALT, reflecting the contribution of AST from sources outside the liver. Hypoalbuminemia and slight increase in total bilirubin have been reported from several studies (41). Abnormal liver biochemistries are uncommon in children (42). Many drugs used in the treatment of COVID-19, such as antipyretic analgesics, antivirals, antibiotics and glucocorticoids, might have potential to cause drug-induced liver injury (43).

Autopsy findings from the first case of COVID-19 patient revealed that the liver tissue showed mild active inflammatory lesions in the hepatic lobular portal area, which suggest liver injury (44). *In vitro* studies have shown that SARS-CoV can cause direct liver injury (45). There is expression of moderate microvascular steatosis and mild lobular and portal activity, which indicate that liver injury could be caused by either SARS-CoV-2 infection or drug-induced liver injury (44).

COVID-19 and the skin

Viral illnesses are mostly associated with cutaneous manifestations, and may have diagnostic or prognostic value. With COVID-19, cutaneous manifestations range from rashes to eruptions.

Morbilloform rash

This is commonly seen with viral exanthemas. Studies from Italy reported that 78% of patients with COVID-19 had an erythematous/morbilloform eruption (46).

Urticaria

A study from France reported that a patient developed an urticarial eruption along with odynophagia and diffuse arthralgia 48 hrs before onset of fever, chills and COVID-19 diagnosis (47). This unusual presentation of urticaria before the more well-known symptoms, signals the possibility that cutaneous eruptions can be a presenting symptom of COVID-19.

Vesicular eruptions

These resembles herpes vesicular eruptions and have been reported in COVID-19 patients (48). It was also observed that the median latency time from COVID-19 systemic symptoms to the rash was 3 days, and the median duration of skin manifestations was 8 days (49).

COVID toes

Research on cutaneous manifestations of coronavirus disease 2019 (COVID-19) are still going on. Acral cutaneous lesions also known as Covid toes have been reported in patients with COVID-19. the pattern of acral lesions is described as erythematous to purple, purpuric macules, papules and/or vesicles (50).

Livedoid eruptions

Many cases of Livedo reticularis-like eruptions have been reported in US patients with COVID-19 (51). It has been hypothesized that SARS-CoV-2 induces immune complexes formation with inflammation and vasculitis. This was further demonstrated on skin biopsies which showed small vessel thrombosis with no viral skin identification (52), demonstrating the possibility that tissue abnormalities are due to systemic toxicity triggered by a disproportionate immune response, rather than to direct viral spread. Another hypothesis is that the virus itself causes vascular damage, binding to ACE-2, which is widely expressed in endothelial cells (35). Early recognition of these cutaneous lesions may help to rapidly start treatment, since their worsening may be related to a severe systemic involvement.

COVID 19 and the neurologic system

Despite the fact that SARS-CoV-2 has been noted to principally affect the respiratory system, many studies have reported the involvement of neurological system. Neurological involvement in COVID-19 has been discussed in three sections; first is neurological features of viral infection, second is post-infective neurological complications, and third is infection in patients with neurological co-morbidity (53). Haematogenous spread and retrograde axonal transport have been described as routes for neuro-invasion by a coronavirus (54). Like other viruses, SARS-CoV-2, has been observed to directly invade the brain leading to clinical encephalitis (55). Other heterogeneous mechanisms such as cytokine storm and secondary hypercoagulability caused by the virus are thought to be involved.

Neurological manifestations in SARS-CoV-2 infection can be grouped into central

nervous system (CNS) and peripheral nervous system (PNS). CNS features include headache, dizziness, ataxia, altered sensorium, encephalitis, stroke and seizures, while PNS features are seen as skeletal muscle injury and peripheral nerve involvement in the form of hyposmia and hypogeusia.

Post infective neurological complications including demyelinating conditions were previously reported (56). Guillain-Barré syndrome (GBS) is an inflammatory polyradiculoneuropathy associated with numerous viral infections. Recently, there have been many case reports describing the association between COVID-19 and GBS. However, despite numerous case reports of GBS associated with COVID-19, the prevalence remains unclear (57). In most of the cases reported, the patients were over 50 years of age, with male predominance (58). Coronavirus infection of the CNS has long provided a model for studying demyelinating diseases such as multiple sclerosis, vaccine design, and novel immunotherapeutic to limit virus spread (59). Even though the neurological manifestations in the majority of infected patients are mild, management of these patients should be a multidisciplinary approach.

The post-mortem nuclear magnetic resonance (NMR) findings of COVID-19 patients were parenchymal brain abnormalities such as subcortical macrobleeds and microbleeds, and edematous changes, which were suggestive of posterior reversible encephalopathy syndrome (PRES), and non-specific changes in the white matter (60).

Conclusion:

SARS-CoV-2 directly damage the lungs, heart, kidneys, liver, skin and brain. However, most of the injuries to these organs is caused by abnormal host immune responses to the virus. In the management of COVID-19 patients, it is recommended that both antiviral and immunomodulatory agents be applied for better prognosis and disease outcome.

References:

1. Li, Q., Guan, X., Wu, P., et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med.* 2020; 382 (13): 1199 – 1207
2. Organization WH. Naming the coronavirus disease (COVID-19) and the virus that causes it. *Braz J Implant Hlth Sci.* 2020; (3): 2.
3. Burki, T. K. Coronavirus in China. *Lancet Resp Med.* 2020; 8 (3): 238.
4. Liu, J., Zheng, X., Tong, Q., et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. *J Med Virol.* 2020; 92 (5): 491-494.

5. Choudhury, A., and Mukherjee, S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. *J Med Virol.* 2020; 92 (10): 2105-2113.
6. Velavan, T. P., and Meyer, C. G. The COVID-19 epidemic. *Trop Med Int Hlth.* 2020; 25 (3): 278.
7. Bi, Q., Wu, Y., Mei, S., et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis.* 2020; 20 (8): 911-919.
8. Moher, D., Liberati, A., Tetzlaff, J., et al. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *Int J Surg.* 2010; 8: 336-341. doi: <https://doi.org/10.1016/j.ijsu.2010.02.007>
9. Gavriatopoulou, M., Korompoki, E., Fotiou, D, et al. Organ-specific manifestations of COVID-19. *Clin Exp Med.* 2020: 1-14.
10. Wu, Z., and McGoogan, J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report
11. Aguiar, D., Lobrinus, J. A., Schibler, M., Fracasso, T., and Lardi, C. Inside the lungs of COVID-19. *Int J Legal Med.* 2020; 134: 1271-1274.
12. Beigee, F. S., Toutkaboni, M. P., Khalili, N., et al. Diffuse alveolar damage and thrombotic microangiopathy are the main histopathological findings in lung tissue biopsy samples of COVID-19 patients. *Pathol Res Pract.* 2020; 216 (10): 153228.
13. Von Stillfried, S., Villwock, S., Bülow, R. D., et al. SARS-CoV-2 RNA screening in routine pathology specimens. *Microb Biotechnol.* 2021; 14 (4): 1627-1641
14. Grimes, Z., Bryce, C., Sordillo, E. M., et al. Fatal pulmonary thromboembolism in SARS-CoV-2-infection. *Cardio Pathol.* 2020; 48: 107227.
15. Massoth, L. R., Desai, N., Szabolcs, A., et al. Comparison of RNA in situ hybridization and immunohistochemistry techniques for the detection and localization of SARS-CoV-2 in human tissues. *Am J Surg Pathol.* 2021; 45 (1): 14-24.
16. Liu, J., Babka, A. M., Kearney, B. J., et al. Molecular detection of SARS-CoV-2 in formalin-fixed, paraffin-embedded specimens. *JCI Insight.* 2020; (12): 5.
17. Buja, L. M., Wolf, D. A., Zhao, B., et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. *Cardio Pathol.* 2020; 48: 107233.
18. Elsoukary, S. S., Mostyka, M., Dillard, A., et al. Autopsy findings in 32 patients with COVID-19: a single-institution experience. *Pathobiol.* 2021; 88 (1): 55-67.
19. Varga, Z., Flammer, A. J., Steiger, P., et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet.* 2020; 395 (10234): 1417-1418.
20. Tavazzi, G., Pellegrini, C., Maurelli, M., et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. *Euro J Heart Failure.* 2020; 22 (5): 911-915.
21. Schaller, T., Hirschbühl, K., Burkhardt, K., et al. Post-mortem examination of patients with COVID-19. *JAMA.* 2020; 323 (24): 2518-2520.
22. Fox, S. E., Li, G., Akmatbekov, A., et al. Unexpected features of cardiac pathology in COVID-19. *Circulation.* 2020; 142 (11): 1123-1125.
23. Pollack, A., Kontorovich, A. R., Fuster, V., and Dec, G. W. Viral myocarditis-diagnosis, treatment options, and current controversies. *Nat Rev Cardiol.* 2015; 12 (11): 670-680.
24. Madjid, M., Safavi-Naeini, P., Solomon, S. D., and Vardeny, O. Potential effects of coronaviruses on the cardiovascular system: A review. *JAMA Cardiol.* 2020; 5 (7): 831-840.
25. Chen, N., Zhou, M., Dong, X., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. *Lancet.* 2020; 395 (10223): 507-513.
26. Bai, Y., Yao, L., Wei, T., et al. Presumed asymptomatic carrier transmission of COVID-19. *JAMA.* 2020; 323 (14): 1406-1407.
27. Wang, Y., Kang, H., Liu, X., and Tong, Z. Asymptomatic cases with SARS-CoV-2 infection. *J Med Virol.* 2020; 92 (9): 1401-1403.
28. Letko, M., Marzi, A., and Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol.* 2020; 5 (4): 562-569.
29. Joannidis, M., Forni, L. G., Klein, S. J., et al. Lung-kidney interactions in critically ill patients: consensus report of the Acute Disease Quality Initiative (ADQI) 21 Workgroup. *Intensive Care Med.* 2020; 46 (4): 654-672.
30. Yang, X., Yu, Y., Xu, J., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Resp Med.* 2020; 8 (5): 475-481.
31. KDIGO clinical practice guideline for acute kidney injury. *Kidney Int Suppl.* 2012; 2: 1-138.
32. Perico, L., Benigni, A., and Remuzzi, G. Should COVID-19 concern nephrologists? Why and to what extent? The emerging impasse of angiotensin blockade. *Nephron.* 2020; 144 (5): 213-221.
33. Maghool, F., Valiani, A., Safari, T., Emami, M. H., and Mohammadzadeh, S. Gastrointestinal and renal complications in SARS-CoV-2-infected patients: Role of immune system. *Scand J Immunol.* 2021; 93: e12999. <https://doi.org/10.1111/sji.12999>
34. Aleebrahim-Dehkordi, E., Reyhanian, A., Saberi-anpour, S., and Hasanpour-Dehkordi, A. Acute kidney injury in COVID-19: Review on current knowledge. *J Nephropathol.* 2020; 9 (4): 31.
35. Hamming, I., Timens, W., Bulthuis, M., et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol.* 2004; 203 (2): 631-637.
36. Peiris, J. S. M., Chu, C-M., Cheng, V. C-C., et al. Clinical progression and viral load in a community outbreak of coronavirus - associated SARS pneumonia: a prospective study. *Lancet.* 2003; 361 (9371): 1767-1772.
37. Su, S., Shen, J., Zhu, L., et al. Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges. *Therap Adv Gastroenterol.* 2020; 13: 1756284820934626.
38. Liang, W., Feng, Z., Rao, S., et al. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. *Gut.* 2020; 69 (6): 1141-1143.
39. Menter, T., Haslbauer, J. D., Nienhold, R., et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. *Histopathol.* 2020; 77 (2):198-209. doi: 10.1111/his.14134
40. Qi, F., Qian, S., Zhang, S., and Zhang, Z. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. *Biochem Biophys Res Comm.* 2020; 526 (1): 135-140.
41. Wang, D., Hu, B., Hu, C., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA.* 2020; 323 (11): 1061-1069.
42. D'Antiga, L. Coronaviruses and immunosuppressed

- patients: The facts during the third epidemic. *Liver Transplantation*. 2020; 26 (6): 832-834.
43. Lu, H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). *Biosci Trends*. 2020; 14 (1): 69-71.
 44. Xu, L., Liu, J., Lu, M., Yang, D., and Zheng, X. Liver injury during highly pathogenic human coronavirus infections. *Liver Int*. 2020; 40 (5): 998-1004.
 45. Tan, Y-J., Fielding, B. C., Goh, P-Y., et al. Overexpression of 7a, a protein specifically encoded by the severe acute respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathway. *J Virol*. 2004; 78 (24): 14043-14047.
 46. Galván, C. C., Catala, A., Carretero, H. G., et al. Classification of cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. *Br J Dermatol*. 2020; 183 (1): 71-77.
 47. Tang, K., Wang, Y., Zhang, H., et al. Cutaneous manifestations of the Coronavirus Disease 2019 (COVID-19): A brief review. *Dermatol Therap*. 2020; 33 (4): e13528.
 48. Kaya, G., Kaya, A., and Saurat, J-H. Clinical and histopathological features and potential pathological mechanisms of skin lesions in COVID-19: Review of the literature. *Dermatopathol*. 2020; 7 (1): 3-16.
 49. Giavedoni, P., Podlipnik, S., Pericàs, J. M., et al. Skin manifestations in COVID-19: prevalence and relationship with disease severity. *J Clin Med*. 2020; 9 (10): 3261.
 50. Hernandez, C., and Bruckner, A. L. Focus on "COVID toes". *JAMA Dermatol*. 2020; 156 (9):1003.
 51. Manalo, I. F., Smith, M. K., Cheeley, J., and Jacobs, R. A. Dermatologic manifestation of COVID-19: Transient livedo reticularis. *J Amer Acad Dermatol*. 2020; 83 (2): 700.
 52. Yao, X., Li, T., He, Z., et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. *Chinese J Pathol*. 2020; 49: E009.
 53. Lahiri, D., and Ardila, A. COVID-19 pandemic: a neurological perspective. *Cureus*. 2020; (4) 12.
 54. Desforges, M., Le Coupanec, A., Dubeau, P, et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? *Viruses*. 2020; 12 (1): 14.
 55. Wang, D., Ju, X., Xie, F., et al. Clinical analysis of 31 cases of 2019 novel coronavirus infection in children from six provinces (autonomous region) of northern China. *Zhonghua er Ke Za Zhi*. 2020: 269-274.
 56. Yeh, E. A., Collins, A., Cohen, M. E., Duffner, P. K., and Faden, H. Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis. *Paediatrics*. 2004; 113 (1): 73-76.
 57. Caress, J. B., Castoro, R. J., Simmons, Z., et al. COVID-19-associated Guillain-Barré syndrome: The early pandemic experience. *Muscle and Nerve*. 2020; 62 (4): 485-491.
 58. Mao, L., Jin, H., Wang, M., et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. *JAMA Neurol*. 2020; 77 (6): 683-690.
 59. Bergmann, C. C., Lane, T. E., and Stohlman, S. A. Coronavirus infection of the central nervous system: host-virus stand-off. *Nat Rev Microbiol*. 2006; 4 (2): 121-132.
 60. Coolen, T., Lolli, V., Sadeghi, N., et al. Early post-mortem brain MRI findings in COVID-19 non-survivors. *Neurol*. 2020; 95: e2016-e2027. doi:10.1212/WNL.0000000000010116